Boulevard Bio
PrivateLast Round
Launch Financing
Aug 12, 2026
Momentum
Top 5%
of companies Caplight tracks
Company Overview
Boulevard Bio is a biotechnology company that develops multi-specific antibodies for the treatment of B cell-driven autoimmune diseases.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Precision Medicine, Drug Discovery, Clinical Trials
Business Model
B2B
Customer Profile
Services & Consulting
AI Layer
Non-AI
Keywords
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Boulevard Bio Comparables
Compare Boulevard Bio with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Oblenio Bio | 88% | |
| Kali Therapeutics | 88% | |
| UCB | 79% |
Boulevard Bio Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Launch Financing | Aug 12, 2026 |
Boulevard Bio Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Deerfield Management | Launch Financing |
Market signals
Structured signals derived from secondary market and firmographic data.
- Aug 12, 2026
$65M raised with Deerfield Management leading.
Recent news
Latest coverage and updates
- is_developingAug 13, 2026
Boulevardbio is developing bispecific antibody BLVD101 on Aug 13th '26.
- is_developingAug 12, 2026
Boulevard Bio is developing several next-generation therapies targeting B-cell-driven autoimmune disease.
- receives_financingAug 12, 2026
Boulevard Bio received financing of $65M in Series A on Aug 12th '26.
Boulevard Bio Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Request accessFrequently Asked Questions
Common questions about Boulevard Bio's valuation, stock price, and market status.
Is Boulevard Bio a public or private company?
Boulevard Bio is a private company.
What is the current stock price of Boulevard Bio?
Boulevard Bio is a private company with no public stock price. Caplight tracks Boulevard Bio's secondary market activity and provides MarketPrice™ estimates to Caplight users.
How much is Boulevard Bio worth (valuation)?
Valuation information for Boulevard Bio is not publicly available.
Can I buy Boulevard Bio stock?
Boulevard Bio shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors. Visit https://www.caplight.com to learn more.
When was Boulevard Bio's last funding round?
Boulevard Bio's most recent funding round was Early Funding on August 12, 2026.
Who are the main investors in Boulevard Bio?
Key investors in Boulevard Bio include Deerfield Management.
Will Boulevard Bio IPO soon?
No public IPO plans have been announced for Boulevard Bio.
How can I track Boulevard Bio secondary market activity?
Caplight tracks bids, offers, and trades for private companies. Visit https://www.caplight.com to monitor Boulevard Bio's secondary market activity and sign up for updates.